scholarly journals Analysis of Teratogenic Effects of Maternal Treatment with 2‐Bromopropane in Mice

2003 ◽  
Vol 45 (1) ◽  
pp. 63-65 ◽  
Author(s):  
Hitoshi Ishikawa ◽  
Toru Yamauchi
1994 ◽  
Vol 153 (7) ◽  
pp. 488-491
Author(s):  
A. Artlich ◽  
Jens M�ller ◽  
Alexander Tschakaloff ◽  
Eberhard Schwinger ◽  
Klaus Kruse ◽  
...  

1994 ◽  
Vol 35 (2) ◽  
pp. 260-260
Author(s):  
Andreas Artlich ◽  
Jens Môller ◽  
Alexander Tschakaloff ◽  
Eberhard Schwinger ◽  
Klaus Kruse ◽  
...  

1994 ◽  
Vol 153 (7) ◽  
pp. 488-491
Author(s):  
A. Artlich ◽  
J. Möller ◽  
K. Kruse ◽  
L. Gortner ◽  
A. Tschakaloff ◽  
...  

GYNECOLOGY ◽  
2020 ◽  
Vol 21 (6) ◽  
pp. 12-15
Author(s):  
Elena V. Tsallagova ◽  
Vasily O. Generalov ◽  
Timur R. Sadykov

Pregnancy is the most dangerous period in terms of interruption of even persistent and long-term remission. At the same time increasing the dose of anticonvulsant increases the risk of teratogenic effects. Aim. to assess the possibility of using progesterone to prevent relapse of epileptic seizures during pregnancy. Materials and methods. 38 pregnant patients with epilepsy with clinical remission before pregnancy, with relapse of epileptic seizures in I trimester of pregnancy, age 31.81.4 years. Dydrogesterone in a dose of 10 to 60 mg/day was prescribed after the relapse of remission. Anticonvulsant dosage was not changed. The blood progesterone concentration and EEG control was carried out. Results. During pregnancy, the level of progesterone in the blood gradually increased from 77.8 nmol/l at 78 weeks of pregnancy to 521.1 nmol/l at 3637 weeks of pregnancy, without exceeding the limits. EEG results did not deteriorate. None of the patients had seizures during pregnancy. Conclusion. Progesterone therapy is an adequate and safe alternative to increasing the dose of anticonvulsants in case of recurrent seizures during pregnancy.


2016 ◽  
Vol 88 (8) ◽  
pp. 713-830
Author(s):  
John H. Duffus ◽  
Michael Schwenk ◽  
Douglas M. Templeton

Abstract The primary objective of this glossary is to give clear definitions for those who contribute to studies relevant to these disciplines, or who must interpret them, but are not themselves reproductive physiologists or physicians. This applies especially to chemists who need to understand the literature of reproductive and teratogenic effects of substances without recourse to a multiplicity of other glossaries or dictionaries. The glossary includes terms related to basic and clinical reproductive biology and teratogenesis, insofar as they are necessary for a self-contained document, particularly terms related to diagnosing, measuring, and understanding the effects of substances on the embryo, the fetus, and on the male and female reproductive systems. The glossary consists of about 1200 primary alphabetical entries and includes Annexes of common abbreviations and examples of chemicals with known effects on human reproduction and development. The authors hope that toxicologists, pharmacologists, medical practitioners, risk assessors, and regulatory authorities are among the groups who will find this glossary helpful, in addition to chemists. In particular, the glossary should facilitate the worldwide use of chemical terminology in relation to occupational and environmental risk assessment.


Lupus ◽  
2021 ◽  
pp. 096120332110214
Author(s):  
Hoda MM Abdulaziz ◽  
Rasha Samir Shemies ◽  
Mohamed Taman ◽  
Alaa Mosbah ◽  
Ghada Elkannishy

Background Mycophenolate mofetil (MMF) is currently used in a wide spectrum of autoimmune diseases and has been rendered very effective in the management of systemic lupus erythematosus and lupus nephritis. MMF is known to be teratogenic (FDA category D) and therefore, women in childbearing period receiving MMF should be counselled to use effective contraceptive methods to avoid an unplanned pregnancy. Case A 22-year-old lady accidentally discovered to be pregnant while using MMF as a treatment of lupus nephritis which was replaced later on by azathioprine. After maternal and fetal evaluation, maternal lupus flare was confirmed and multiple fetal skeletal deformities associated with intrauterine growth restriction (IUGR) were diagnosed by 4-dimensional ultrasound. Termination of pregnancy was decided after shared decision making. Conclusion Women in childbearing period should be advised to postpone pregnancy for at least six weeks after stoppage of MMF therapy because of its potential teratogenic effects during pregnancy.


2017 ◽  
Vol 337 ◽  
pp. 1-11 ◽  
Author(s):  
Maria Natalia Calienni ◽  
Daniela Agustina Feas ◽  
Daniela Edith Igartúa ◽  
Nadia Silvia Chiaramoni ◽  
Silvia del Valle Alonso ◽  
...  

1990 ◽  
Vol 32 (5) ◽  
pp. 502-507 ◽  
Author(s):  
Tohru Sonoda ◽  
Shozo Ohdo ◽  
Ken-ichi Ohba ◽  
Takahiro Okishima ◽  
Kunio Hayakawa

Sign in / Sign up

Export Citation Format

Share Document